GlobeNewswire: Denali Therapeutics Inc. Contains the last 10 of 97 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T08:34:26ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2024/02/27/2836005/0/en/Denali-Therapeutics-Reports-Fourth-Quarter-and-Full-Year-2023-Financial-Results-and-Business-Highlights.html?f=22&fvtc=4&fvtv=42915Denali Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights2024-02-27T13:05:54Z<![CDATA[SOUTH SAN FRANCISCO, Calif., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for the treatment of neurodegenerative diseases and lysosomal storage diseases, today reported financial results for the fourth quarter and year ended December 31, 2023, and provided business highlights.]]>https://www.globenewswire.com/news-release/2024/02/27/2835991/0/en/Denali-Therapeutics-Announces-500-million-Private-Placement-Equity-Financing.html?f=22&fvtc=4&fvtv=42915Denali Therapeutics Announces $500 million Private Placement Equity Financing2024-02-27T13:00:37Z<![CDATA[SOUTH SAN FRANCISCO, Calif., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for the treatment of neurodegenerative diseases and lysosomal storage diseases, today announced that the company has entered into a securities purchase agreement with certain existing accredited investors to issue and sell an aggregate of 3,244,689 shares of its common stock at a price of $17.07 per share and pre-funded warrants to purchase 26,046,065 shares of common stock at a purchase price of $17.06 per pre-funded warrant share, through a private investment in public equity (PIPE) financing. The pre-funded warrants will have an exercise price of $0.01 per share of common stock, be immediately exercisable, and remain exercisable until exercised in full. Denali anticipates the gross proceeds from the PIPE to be approximately $500 million. The financing is expected to close on February 29, 2024, subject to customary closing conditions. Proceeds from the financing are expected to be used to support Denali’s ongoing research and development activities, the acceleration and expansion of its proprietary BBB-crossing Transport Vehicle (TV) technology, as well as general corporate purposes and working capital.]]>https://www.globenewswire.com/news-release/2024/02/07/2825115/0/en/Denali-Therapeutics-Announces-New-Data-and-Expansion-of-Its-Blood-Brain-Barrier-BBB-Crossing-Enzyme-Replacement-Therapy-Programs-at-WORLDSymposium.html?f=22&fvtc=4&fvtv=42915Denali Therapeutics Announces New Data and Expansion of Its Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapy Programs at WORLDSymposium™2024-02-07T13:00:00Z<![CDATA[SOUTH SAN FRANCISCO, Calif., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for the treatment of neurodegenerative diseases and lysosomal storage diseases, today announced new data presentations highlighting the broad potential of its BBB-crossing enzyme replacement therapies in development for the treatment of mucopolysaccharidoses (MPS). New clinical data on tividenofusp alfa (DNL310) in MPS II (Hunter syndrome) and mouse model data on DNL126 (ETV:SGSH) in MPS IIIA (Sanfilippo syndrome type A) are being presented this week at the 20th Annual WORLDSymposium™ in San Diego, California.]]>https://www.globenewswire.com/news-release/2024/02/01/2821926/0/en/Denali-Therapeutics-Announces-Presentations-on-Its-Investigational-Blood-Brain-Barrier-BBB-Crossing-Enzyme-Replacement-Therapies-at-the-Upcoming-2024-WORLDSymposium.html?f=22&fvtc=4&fvtv=42915Denali Therapeutics Announces Presentations on Its Investigational Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapies at the Upcoming 2024 WORLDSymposium™2024-02-01T13:00:00Z<![CDATA[SOUTH SAN FRANCISCO, Calif., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for the treatment of neurodegenerative diseases and lysosomal storage diseases, today announced upcoming presentations from its Enzyme Transport Vehicle (ETV) development programs, tividenofusp alfa (DNL310) and DNL126 (ETV:SGSH), to be given at the 20th Annual WORLDSymposium™, which will be held February 4-9, 2024, in San Diego, California.]]>https://www.globenewswire.com/news-release/2024/01/08/2805400/0/en/Denali-Therapeutics-Announces-Key-Anticipated-2024-Milestones-and-Priorities-to-Further-Advance-Its-Therapeutics-Portfolio-for-Neurodegeneration-and-Lysosomal-Storage-Diseases.html?f=22&fvtc=4&fvtv=42915Denali Therapeutics Announces Key Anticipated 2024 Milestones and Priorities to Further Advance Its Therapeutics Portfolio for Neurodegeneration and Lysosomal Storage Diseases2024-01-08T13:00:00Z<![CDATA[SOUTH SAN FRANCISCO, Calif., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for the treatment of neurodegenerative diseases and lysosomal storage diseases, today announced program progress and expected milestones for 2024, which Chief Executive Officer, Ryan Watts, Ph.D., will highlight during a corporate presentation at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9th, at 10:30 a.m. Pacific Time.]]>https://www.globenewswire.com/news-release/2023/11/07/2775548/0/en/Denali-Therapeutics-Reports-Third-Quarter-2023-Financial-Results-and-Business-Highlights.html?f=22&fvtc=4&fvtv=42915Denali Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights2023-11-07T21:01:00Z<![CDATA[SOUTH SAN FRANCISCO, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for the treatment of neurodegenerative diseases and lysosomal storage diseases, today reported financial results for the third quarter ended September 30, 2023, and provided business highlights.]]>https://www.globenewswire.com/news-release/2023/08/30/2734330/0/en/Denali-Therapeutics-Announces-New-Interim-Data-from-Phase-1-2-Study-of-DNL310-ETV-IDS-in-MPS-II-Hunter-Syndrome-at-SSIEM-2023.html?f=22&fvtc=4&fvtv=42915Denali Therapeutics Announces New Interim Data from Phase 1/2 Study of DNL310 (ETV:IDS) in MPS II (Hunter Syndrome) at SSIEM 20232023-08-30T12:30:00Z<![CDATA[SOUTH SAN FRANCISCO, Calif., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier for the treatment of neurodegenerative diseases and lysosomal storage diseases, today announced new interim data from the ongoing open-label, single-arm Phase 1/2 study of DNL310 (ETV:IDS) in children with MPS II (Hunter syndrome). DNL310 is an investigational enzyme replacement therapy designed to cross the BBB and address the behavioral, cognitive, and physical manifestations of MPS II. The interim data from the Phase 1/2 study of DNL310 were highlighted in an oral presentation at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium 2023 in Jerusalem, Israel. A PDF of the Phase 1/2 presentation is available on Denali’s website on the Events page of the Investor section.]]>https://www.globenewswire.com/news-release/2023/08/08/2721096/0/en/Denali-Therapeutics-Reports-Second-Quarter-2023-Financial-Results-and-Business-Highlights.html?f=22&fvtc=4&fvtv=42915Denali Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights2023-08-08T20:01:27Z<![CDATA[SOUTH SAN FRANCISCO, Calif., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for the treatment of neurodegenerative diseases and lysosomal storage diseases, today reported financial results for the second quarter ended June 30, 2023, and provided business highlights.]]>https://www.globenewswire.com/news-release/2023/06/20/2690912/0/en/Denali-Therapeutics-Announces-Robust-Reduction-in-Neurofilament-Light-NfL-with-DNL310-ETV-IDS-Treatment-in-MPS-II-Hunter-Syndrome.html?f=22&fvtc=4&fvtv=42915Denali Therapeutics Announces Robust Reduction in Neurofilament Light (NfL) with DNL310 (ETV:IDS) Treatment in MPS II (Hunter Syndrome)2023-06-20T11:00:00Z<![CDATA[SOUTH SAN FRANCISCO, Calif., June 20, 2023 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier for the treatment of neurodegenerative diseases and lysosomal storage diseases, today announced new interim results from the ongoing open-label, single-arm Phase 1/2 study of DNL310 (ETV:IDS) in children with MPS II (Hunter syndrome). Among the 13 participants who reached two years of treatment at the time of the interim analysis, a mean reduction of 64% (p<0.001) from baseline in serum neurofilament light (NfL) was observed. The U.S. Food and Drug Administration (FDA) recently recommended to Denali the assessment of NfL as an exploratory endpoint to assess its potential as a possible biomarker to assess diagnostic, prognostic, or therapeutic response in subjects with neuronopathic MPS II. DNL310 is an investigational brain-penetrant enzyme replacement therapy designed to address the behavioral, cognitive, and physical manifestations of MPS II. The global Phase 2/3 COMPASS study is ongoing.]]>https://www.globenewswire.com/news-release/2023/05/08/2663803/0/en/Denali-Therapeutics-Reports-First-Quarter-2023-Financial-Results-and-Business-Highlights.html?f=22&fvtc=4&fvtv=42915Denali Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights2023-05-08T20:01:00Z<![CDATA[SOUTH SAN FRANCISCO, Calif., May 08, 2023 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for the treatment of neurodegenerative diseases and lysosomal storage diseases, today reported financial results for the first quarter ended March 31, 2023, and provided business highlights.]]>